Inova Dwight and Martha Schar Cancer Institute Names Leading Experts in Cancer Care, Research and Administration
FALLS CHURCH, VA – October 28, 2015 – Inova today announced the addition of two leaders who will bring new scientific and administrative expertise to the Inova Dwight and Martha Schar Cancer Institute (ISCI), an international center for advanced cancer care and research. Collaborating with clinical and scientific partners, ISCI conducts genomic, clinical and translational research to better understand, predict, prevent, and eliminate cancer.
Jeanny Aragon-Ching, MD, FACP, is a nationally recognized genitourinary (GU) medical oncologist with particular expertise in prostate, bladder, and kidney cancers. At ISCI, Dr. Aragon-Ching serves as the clinical program director of genitourinary cancers, where she will lead the multidisciplinary program of excellence in clinical care and research for patients with GU malignancies. Prior to joining ISCI, Dr. Aragon-Ching served as an associate professor of medicine at the George Washington University School of Medicine and Health Sciences, where she also served as a principal investigator of many trials on drug treatment and biomarkers in GU cancer. Dr. Aragon-Ching is a well-established clinician and has authored over 60 publications including papers in high-impact journals such as Clinical Cancer Research, Journal of Urology and the Lancet.
Thomas Graves, FACHE has joined ISCI as Vice President for Cancer Services and Associate Director for Administration. Mr. Graves has previously held administrative leadership positions in nationally recognized cancer institutes such as the MD Anderson Cancer Center in Houston and the University of Texas San Antonio Cancer Center. He comes to Inova most recently from Geisinger Health System (GHS) where as Vice President of Cancer Services, he led the development of administrative oversight systems for cancer patients throughout the GHS. In his role at Inova, Mr. Graves will have administrative responsibility for critical infrastructure to facilitate the development of comprehensive ISCI clinical care and translational research programs. These programs will make important clinical trials available to all individuals cared for in the Inova Health System and to apply patient-centered, evidence-based multidisciplinary systems of care for all ISCI patients.
“We’re excited to welcome Jeanny and Tom to Inova,” said Donald Trump, MD. “My goal is to build an exceptional team of administrative leaders and clinical/translational physicians and researchers who bring substantial specialized expertise in cancer care and research to offer innovative precision treatments. Jeanny’s and Tom’s experience and expertise in oncology and administration will substantially accelerate our work to bring patient-centered, multidisciplinary, precision care to all of our patients.”
ISCI will be a cornerstone of the new Inova Center for Personalized Health (ICPH), announced earlier this year. ICPH will lead the way in the integration of genomics into personalized medicine and individualized wellness. This personalized health approach enables ISCI to create individualized treatments and preventive analytics to predict illness for every unique individual and family it serves.
Media Contact: Kelly Schlageter, kelly.schlageter@inova.org